NovaBridge Biosciences
NBP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | -$0 | $0 |
| % Growth | -100% | 141.9% | -112.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | $0 |
| % Margin | – | 100% | 2,325.8% | 47.3% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $1 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | $1 |
| Operating Expenses | $0 | $1 | $0 | $2 |
| Operating Income | -$0 | -$1 | -$0 | -$2 |
| % Margin | – | -11,395.1% | 3,422.2% | -2,353.1% |
| Other Income/Exp. Net | $0 | -$1 | -$1 | -$0 |
| Pre-Tax Income | -$0 | -$1 | -$1 | -$2 |
| Tax Expense | $0 | -$1 | $0 | -$0 |
| Net Income | -$0 | -$1 | -$3 | -$2 |
| % Margin | – | -32,674% | 23,438.9% | -2,648.7% |
| EPS | -4.46 | -17.62 | -30.38 | -30.7 |
| % Growth | 74.7% | 42% | 1% | – |
| EPS Diluted | -4.46 | -17.62 | -30.38 | -30.68 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$2 |
| % Margin | – | -7,674.2% | 478.9% | -2,337.4% |